Concepedia

Publication | Open Access

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

DOIFull Paper Access

93

Citations

28

References

2018

Year

Alberto Carretero-González, David Lora, Ismael Ghanem, Jon Zugazagoitia, Daniel Castellano, Juan Manuel Sepúlveda-Sánchez, José A. López-Martín, Luis Paz‐Ares, Guillermo de Velasco
Oncotarget

Abstract

In this systematic meta-analysis, anti-PD1/PD-L1 mAbs were associated with a greater overall response rate. Patients with melanoma and those managed in the first line setting seem to have an additional benefit with anti-PD1/PD-L1 mAbs.

References

YearCitations

Page 1